Multicentre evaluation of magnetic resonance imaging supported transperineal prostate biopsy in biopsy‐naïve men with suspicion of prostate cancer

To analyse the detection rates of primary magnetic resonance imaging (MRI)‐fusion transperineal prostate biopsy using combined targeted and systematic core distribution in three tertiary referral centres.

[1]  A. Prando.  Prostate tumor volume measurement with combined T2-weighted imaging and diffusion-weighted MR: correlation with pathologic tumor volume , 2009 .

[2]  Tristan Barrett,et al.  Multicentre evaluation of targeted and systematic biopsies using magnetic resonance and ultrasound image‐fusion guided transperineal prostate biopsy in patients with a previous negative biopsy , 2017, BJU international.

[3]  Heinz-Peter Schlemmer,et al.  Comparative analysis of transperineal template saturation prostate biopsy versus magnetic resonance imaging targeted biopsy with magnetic resonance imaging-ultrasound fusion guidance. , 2015, The Journal of urology.

[4]  M. Stifelman,et al.  A prospective, blinded comparison of magnetic resonance (MR) imaging-ultrasound fusion and visual estimation in the performance of MR-targeted prostate biopsy: the PROFUS trial. , 2014, European urology.

[5]  David Y. Lu,et al.  Characteristics of Detected and Missed Prostate Cancer Foci on 3-T Multiparametric MRI Using an Endorectal Coil Correlated With Whole-Mount Thin-Section Histopathology. , 2015, AJR. American journal of roentgenology.

[6]  F. Beuvon,et al.  Tumor target volume for focal therapy of prostate cancer-does multiparametric magnetic resonance imaging allow for a reliable estimation? , 2014, The Journal of urology.

[7]  A. Svindland,et al.  Detection of the index tumour and tumour volume in prostate cancer using T2‐weighted and diffusion‐weighted magnetic resonance imaging (MRI) alone , 2014, BJU international.

[8]  W. Catalona,et al.  Diagnostic Value of Guided Biopsies: Fusion and Cognitive-registration Magnetic Resonance Imaging Versus Conventional Ultrasound Biopsy of the Prostate. , 2016, Urology.

[9]  A. Doble,et al.  The influence of prostate‐specific antigen density on positive and negative predictive values of multiparametric magnetic resonance imaging to detect Gleason score 7–10 prostate cancer in a repeat biopsy setting , 2017, BJU international.

[10]  R. Miano,et al.  Magnetic Resonance and Ultrasound Image Fusion Supported Transperineal Prostate Biopsy Using the Ginsburg Protocol: Technique, Learning Points, and Biopsy Results. , 2016, European urology.

[11]  Andrew J. Vickers,et al.  NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

[12]  A Hayen,et al.  The Diagnostic Performance of Multiparametric Magnetic Resonance Imaging to Detect Significant Prostate Cancer. , 2016, The Journal of urology.

[13]  A. Rosenkrantz,et al.  Predictive value of negative 3T multiparametric magnetic resonance imaging of the prostate on 12‐core biopsy results , 2016, BJU international.

[14]  M. Roethke,et al.  Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies. , 2017, European urology.

[15]  M. Parmar,et al.  Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confi rmatory study , 2018 .

[16]  P L Choyke,et al.  PI-RADS version 2: what you need to know. , 2015, Clinical radiology.

[17]  M. Ghilezan,et al.  High-Risk Prostate Cancer , 2011 .

[18]  Tristan Barrett,et al.  Defining the learning curve for multiparametric magnetic resonance imaging (MRI) of the prostate using MRI‐transrectal ultrasonography (TRUS) fusion‐guided transperineal prostate biopsies as a validation tool , 2016, BJU international.

[19]  J. Fütterer,et al.  Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group. , 2013, European urology.

[20]  H. G. van der Poel,et al.  What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel. , 2017, European urology.

[21]  Baris Turkbey,et al.  Low suspicion lesions on multiparametric magnetic resonance imaging predict for the absence of high‐risk prostate cancer , 2012, BJU international.

[22]  Tristan Barrett,et al.  Comparison of initial and tertiary centre second opinion reads of multiparametric magnetic resonance imaging of the prostate prior to repeat biopsy , 2016, European Radiology.

[23]  J. Yaxley,et al.  Comparison between target magnetic resonance imaging (MRI) in‐gantry and cognitively directed transperineal or transrectal‐guided prostate biopsies for Prostate Imaging–Reporting and Data System (PI‐RADS) 3–5 MRI lesions , 2017, BJU international.

[24]  T. Miyagawa,et al.  Combination of prostate imaging reporting and data system (PI‐RADS) score and prostate‐specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients , 2017, BJU international.

[25]  Xavier Leroy,et al.  Prostate cancer diagnosis: multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy--prospective multicenter study. , 2013, Radiology.

[26]  L. Egevad,et al.  The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma , 2005, The American journal of surgical pathology.

[27]  P. Carroll,et al.  NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

[28]  Christina Hulsbergen-van de Kaa,et al.  Results of Targeted Biopsy in Men with Magnetic Resonance Imaging Lesions Classified Equivocal, Likely or Highly Likely to Be Clinically Significant Prostate Cancer. , 2017, European urology.

[29]  Jason A Koutcher,et al.  Prostate tumor volume measurement with combined T2-weighted imaging and diffusion-weighted MR: correlation with pathologic tumor volume. , 2009, Radiology.

[30]  A. Zitella,et al.  Prostate Cancer Detection Rate with Koelis Fusion Biopsies versus Cognitive Biopsies: A Comparative Study , 2016, Urologia Internationalis.

[31]  B. Vainer,et al.  Risk of prostate cancer diagnosis and mortality in men with a benign initial transrectal ultrasound-guided biopsy set: a population-based study. , 2017, The Lancet. Oncology.

[32]  David Y. Lu,et al.  Multifocality and prostate cancer detection by multiparametric magnetic resonance imaging: correlation with whole-mount histopathology. , 2015, European urology.

[33]  Baris Turkbey,et al.  Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. , 2015, JAMA.

[34]  M. Roethke,et al.  Definitions of terms, processes and a minimum dataset for transperineal prostate biopsies: a standardization approach of the Ginsburg Study Group for Enhanced Prostate Diagnostics , 2013, BJU international.

[35]  T. H. van der Kwast,et al.  EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. , 2014, European urology.

[36]  M. Roethke,et al.  Multiparametric Magnetic Resonance Imaging (MRI) and MRI-Transrectal Ultrasound Fusion Biopsy for Index Tumor Detection: Correlation with Radical Prostatectomy Specimen. , 2016, European urology.

[37]  J. Fütterer,et al.  ESUR prostate MR guidelines 2012 , 2012, European Radiology.